Cell based assays are the most accurate method of cell testing, due to the fact that live cells are utilized for experiments.
Thus, efforts have been dedicated to developing cell-based high throughput screening (HTS) platforms that can provide more relevant in vivo biological information than biochemical assays and thus reduce the number of animal tests and accelerate the drug discovery process.
We are thrilled to present the 8th annual conference in the industry leading series, Advances in Cell Based Assays, taking place on 10th & 11th November 2015 in Central London, UK.
Due to improvements in detection technology and sensitivity in drug screening, recent reports predict the
cell based assays market to reach $4.7 billion in 2016. With a fresh new agenda for 2015,
Advances in Cell Based Assays arrives at the perfect time to expand scientific horizons in key topics such as drug toxicity testing, live imaging, 3D modelling, phenotype screening, formulation in assay development, plus much more!
We have worked closely with AstraZeneca, GSK, Pfizer and Johnson & Johnson, to create a packed programme and a quality panel of experts to discuss and spark solutions specifically for professionals working in regenerative medicine using 3D cell based assays and high-throughput technologies.
We have created highlight topical sessions including:
- Bioengineering approaches for the derivation and manipulation of iPS cells in regenerative medicine
- Exploiting Gene Expression and Leveraging Signalling Pathway Mechanisms
- High-Throughput Screening in predictive toxicology
- Characterisation of human iPSC-derived Hepatocytes and toxicity mechanisms
- Functional genomic technologies for the identification of novel targets in drug development.
Plus One Interactive Post-Conference Workshop | Thursday 12th November 2015
High-throughput cell and tissue imaging and analysisWorkshop Leader: Aamir Ahmed, Head of Stem Cell and Prostate Cancer Group, Kings College London
Featured Speakers Include:
- Aamir Ahmed, Head of Stem Cell and Prostate Cancer Group, Kings College London
- Alison Howarth, Research Assistant, Oxford University
- Anna Collen, Project Director Pharmaceutical Development, AstraZeneca
- Armin Wolf, Director, Novartis Pharmaceuticals
- Christopher Dunsby, Senior Lecturer, Imperial College
- Clare Gardner, Senior Scientist, Pfizer
- David Gray, Head of Biology, Drug Discovery Unit, University Of Dundee
- Farnaz Fallah-Arani, Senior Group Leader, UCB
- Felicity Rose, Associate Professor in Tissue Engineering, Nottingham University
- Joanna Taylor, Senior Scientist, GlaxoSmithKline
- Martin Main, Director, AstraZeneca
- Nariman Ansari, Project leader, Buchmann Institute for Molecular Life Sciences (BMLS) - Goethe University Frankfurt
- Neil Carragher, Principal Investigator Drug Discovery, University Of Edinburgh
- Rachael Walker, Head of Flow Cytometry, Babraham Institute
- Roderick L. Beijersbergen, Associate Professor and Head NKI Robotics and Screening Centre, The Netherlands Cancer Institute
- Ross Paveley, Senior Scientist, UCB
- Sheraz Gul, Head of Assay Development & Screening, Fraunhofer-IME SP
- Xavier Leroy, Associate Director, Actelion Pharmaceuticals Ltd
- Yolanda Chong, Principal Scientist, Johnson & Johnson
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Venue
Holiday Inn Kensington Forum97 Cromwell Rd,
London, SW7 4DN
United Kingdom
